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Solid phase synthesis was used to produce 5 hybrid peptides containing sequences from the antibacterial peptide, cecropin A, and from the bee 
venom toxin, melittin. Four of these chimeric peptides howed good antibacterial activity against representative Gram-negative and Gram-positive 
bacterial species. The best hybrid, cecropin A(l-13)-melittin(l-13) was IOO-fold more active than cecropin A against Staphylococcus ureus. It was 
also a lo-fold better antimalarial agent than cecropin B or magainin 2. Sheep red cells were lysed by melittin at low concentrations, but not by 
the hybrid molecules, even at 50 times higher concentrations. 
Cecropin A; Melittin; (Staphylococcus aureus, Plasmodium falciparium) 
1. INTRODUCTION 
Cecropins are a family of broad spectrum antibacte- 
rial peptides that constitute a main part of the humoral 
immune system in insects (review [l]). However, 
cecropins may also be widely distributed in the aminal 
kingdom because a cecropin was recently isolated from 
pig intestine [2]. Cecropins are composed of two dif- 
ferent domains linked by a hinge region containing Gly 
or Pro or both. The N-terminal domain is strongly basic 
and forms a nearly perfect amphipathic a-helix, while 
the C-terminus is a more hydrophobic helix [3-61. 
Cecropins act on a wide variety of Gram-positive and 
Gram-negative bacteria but as far as tested they do not 
lyse eucaryotic cells [ 1,3]. 
The bee venom toxin, melittin, has a principal design 
that resembles the cecropins but the polarity is reversed: 
here the N-terminus is hydrophobic and the C-terminus 
is basic [7,8]. Like the cecropins, melittin has a hinge 
region and an amidated C-terminus. In both of the pep- 
tides there is also a conserved tryptophan residue on the 
N-terminal side of the basic residues. As far as known 
cecropin is not toxic, while melittin has a variety of tox- 
ic properties (review [9]). The most recorded function 
of melittin is the ability to lyse red cells. Melittin is also 
antibacterial [lo] although this is not widely recognized. 
struction of the host and the same would in many re- 
spects apply also to toxins. It was therefore interesting 
to make chimeric peptides that are cecropin-melittin 
hybrids and assay them for antibacterial activity and 
ability to lyse red cells. This was a natural extension of 
our earlier work on cecropin analogs with single residue 
substitutions [11,121, on cecropin model peptides [ 131, 
and on a hybrid between cecropins A and D [ 141 with an 
improved ability to form ion channels [15]. Two 
analogs of cecropin B have been reported to inhibit the 
blood stream forms of the malaria parasite [16], and 
recently magainin 2 and cecropin B were found to in- 
hibit the mosquito forms of the parasite [17]. We have 
therefore also tested our most potent hybrid peptide for 
ability to inhibit the growth of the blood stream forms 
of the malaria parasite. 
2. MATERIAL AND METHODS 
2.1. Solid phase synthesis 
The ideal immune substance should act against a 
very wide range of foreign cells without causing any de- 
The new peptides and also melittin were synthesized by a combina- 
tion of manual and automated (Applied Biosystem 320A) solid phase 
techniques as described before in detail [l l-141. The purification was 
first by gel filtration on Sephadex G-25 in 1 M HOAc. The next step 
was low pressure, reverse phase, preparative liquid chromatography 
on a Vydac Cl8 column (218TPBlO) and elution with a linear gradient 
of 2%65% acetonitrile. The molecular weight of the peptides was 
determined by fission-fragment mass spectrometry. Synthetic 
magainin 2 with a C-terminal amide and PGLa were kindly obtained 
from M. Zasloff. 
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2.2. Antibacterial assays 
Part of these results were presented at the FEBS Meeting in Rome, Ju- 
ly 4, 1989 and at the 1 lth American Peptide Symposium in San Diego, 
July 11, 1989 
For each peptide and for each test bacterium 3 ~1 of a series of dilu- 
tions were placed in small wells in thin agarose plates seeded with the 
respective test bacteria. We earlier used agar plates [18] but many 
basic peptides are adsorbed to agar, and agarose gives LC values 
lower by a factor of 2-5 (Zasloff, personal communication). Plates 
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were incubated overnight at 3O”C, the inhibition zones were recorded 
and the lethal concentration for each peptide (LC, the lowest concen- 
tration that inhibits growth) was calculated as described [18]. Since 
large inhibition zones give low LC values, such values are more ac- 
curate than high LC values which come from small zones. 
2.3. Assay of red cell lysis 
This was recorded by an adaptation of the antibacterial inhibition 
zone assay [IS] to plates with sheep red cells (SRC). Sterile agarose 
plates contained 6 ml of medium with 1% agarose, 0.9% NaCl and 
10% SRC suspended in Alsevers solution. A dilution series of peptide 
was applied in 3 mm wells each loaded with 3 ,ul of the respective 
samples. The plates were incubated at 30°C for 24 h, the zones were 
recorded and LC values calculated as described [181. Clear zones were 
recorded after a few hours of incubation and the use of such data gave 
an LC value of the same order as readings after 24 h. This plate assay 
is faster and more convenient han the lysis assay normally used for 
melittin. 
2.4. Antiparasitic assay 
The blood stream forms of the malaria parasite, Plasmodium falci- 
parium, primarily late trophozoites and early schizonts, were assayed 
by recording the inhibition of the reinvasion of human red cells [19]. 
Quadruplicate microcultures of strain F32 (Tanzania) were incubated 
for 20 h at 37°C in a complete tissue culture medium, with or without 
different concentrations of the peptides to be assayed. After acridine 
orange staining, the percentage of newly infected red cells was scored 
in a fluorescence microscope. For each culture 40000 red cells were 
analysed for parasitic infection. 
3. RESULTS 
The sequences of the parent peptides, cecropin A 
(CA) and melittin (M), are given in fig. 1. Assuming that 
the region with a Trp followed by a number of basic 
residues can be termed ‘head’ and that the hydrophobic 
region could be referred to as a ‘tail’, 5 hybrid peptides 











Long, cecropin-like but 
with melittin ‘tail’ 
Short, cecropin-like but 
with melittin ‘tail’ 
Shortened and inverted 
cecropin 
Short, melittin-like with 
cecropin ‘head’ 
Shortened and inverted 
melittin 
The term ‘like’ only refers to whether the basic ‘head’ 
is in the C-terminus as in melittin or in the N-terminus 
1 13 24 25 37 
Cecropin A: KwKLFKKIEKVGQ--NIRDGIIXAGP--AVAVVGQATQIAK 
1 13 16 26 
Melittin: GIGAVLKVLTTGL--PA--LISWIKRKRQC 
Fig. 1. Amino acid sequences of the two parental peptides cecropin A 
and melittin. The break points used in the construction of hybrids are 
indicated by the respective numbers and by two hyphens. The basic 
residues are in bold type. The C-terminals in both parents and all 
hybrid peptides are amidated. 
as for all cecropins. A further attempt to study the ef- 
fects of the polarity was the design of the two inverted 
molecules. 
All peptides were found to be homogeneous by 
analytical HPLC, of correct amino acid composition 
and with expected molecular weights by mass spectro- 
scopy. In addition the parental compounds and 3 of the 
hybrids were investigated with acidic polyacrylamide 
gel electrophoresis by staining of one gel and with over- 
lay of bacteria on another gel [20]. All compounds gave 
sharp bands coinciding with the bactericidal activity as 
scored by the bacterial overlay. 
The peptides were then assayed quantitatively for an- 
tibacterial activity against 2 Gram-negative and 3 
Gram-positive bacteria as well as for lysis of sheep red 
cells (SRC). The results in table 1 show that under the 
present assay condition (with agarose instead of agar in 
the plates) melittin is an even better broad-spectrum an- 
tibiotic than cecropin A. However, melittin is hemolytic 
and caused lysis of SRC at 4-8 PM. When the C- 
terminus in cecropin A was replaced with the sequence 
M(l-13), (the melittin ‘tail’ in hybrids 1 and 2) the bac- 
tericidal activity was increased by a factor of 30-100 in 
case of S. aureus and by a factor of 6-8 in the case of 
B. subtilis. Equally important, these peptides caused no 
lysis of SRC up to 2OOpM. 
It was not possible to make a shortened and inverted 
cecropin (hybrid 3) with activity. However, activity 
against 4 organisms, E. coli, P. aeruginosa, B. subtilis, 
and S. pyogenes was restored in hybrid 4 in which the 
melittin ‘tail’, M(l-13), replaced CA(25-37) in hybrid 
3. This peptide gave doubtful results in two cases: with 
S. aureus the concentration dependence of the inhibi- 
Table 1 
Lethal and lysis concentrations (,uM) for parental compounds and 







D21 0T97 Bsll SaCI Sp 1 SRC 
0.2 2 4 >200 4 >200 
0.8 3 0.2 0.2 0.5 4-8 
(1) CA(l-24)M(l-13) 0.3 1 0.5 6 2 >200 
(2) CA(l-13)M(l-13) 
(3) CA(25-37)CA(l-13) 2:” 
1 0.7 2 1 >200 
300 20 >300 20 >300 
(4) M(l-13)CA(l-13) 5 0.3 1 
(5) M(16-26)M(l-13) A.7 8 0.7 I: 1 
80? 
>200 
Lethal concentrations calculated [18] from inhibition zones on thin 
agarose plates seeded with the respective organisms. Abbreviations 
for the organisms used in the assay plates: D21, Escherichia coli K12; 
OT97, Pseudomonas aeruginosa; Bsll, Bacillus subtilis; SaCI, 
Staphylococcus aureus Cowan I; Sp 1, Streptococcuspyogenes; SRC, 
sheep red cells 
* indicates a very flat concentration dependence 
? indicates turbid zones 
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Peptide concentration (PM ) 
Fig.2. Inhibition of the growth of the blood stream forms of P. falci- 
parium by different amounts of hybrid 2, CA(l-13)M(l-13), and 
four other peptides used for comparison. Details of the assay are 
given in section 2 and in [19]. Duplicate assays were run for hybrid 2. 
tion zones was abnormally flat and with SRC turbid 
zones were obtained. Finally, in the inverted melittin 
(hybrid 5), where the basic ‘head’ was moved from the 
C-terminus to the N-terminus, there was a significant 
antibacterial activity against 3 test species, but still no 
lysis of SRC, two rather surprising results. 
Cecropins A and B and our most potent hybrid, 
CA(l-13)M(l-13), were then assayed for activity 
against the blood stream form of Plasmodium 
fulciparium. For comparison we also included the frog 
skin peptides magainin 2 and PGLa, but melittin could 
not be tested because it is strongly hemolytic. Fig.2 
shows that cecropin A had only negligible activity while 
cecropin B was about as potent as magainin 2. The 
hybrid CA(l-13)M(l-13) was an order of magnitude 
more potent than cecropin B while PGLa had an inter- 
mediate activity. Only a trace of hemolytic activity was 
observed with the hybrid. 
4. DISCUSSION 
Both cecropins and melittin are composed of a 
hydrophilic and a hydrophobic domain that are 
separated by a flexible hinge region. However, the 
polarity of the two peptides is reversed, with the hydro- 
philic and basic region of melittin in the C-terminus 
while in all cecropins the strongly basic region is at the 
N-terminus. In addition, it should be noted that 
cecropin A contains 37 residues while melittin is com- 
posed of only 26. The size of an antibiotic peptide is 
relevant because a large peptide is more likely to be im- 
munogenic than a small one. It is also more difficult 
and expensive to synthesize a larger molecule. The dif- 
ference in size between the two parental peptides is 
therefore quite relevant from a therapeutic aspect. 
We have earlier made truncated cecropins and 
analogs with single residue replacements in the hydro- 
philic part [ 11,121 but in every case obtained peptides 
with more or less decreased antibacterial potency. We 
have also made model peptides containing the first 11 
residues of cecropin A linked to two theoretically con- 
structed fragments that were either amphipathic, flexi- 
ble or hydrophobic [ 131. One of the model peptides 
showed moderate activities and lends support to the 
concept that active cecropins will have to be composed 
of a hydrophilic and a hydrophobic domain linked by a 
hinge region. 
The hybrid (chimeric) concept was first tested on a 
peptide that contained residues I- 11 from cecropin A 
and 12-37 from cecropin D [14]. This compound was 
the first case where we succeeded in improving the over- 
all activity of a cecropin-like molecule. The results in 
table 1 and fig.2 clearly show that the hybrid concept is 
fruitful and that it can give antimicrobial peptides with 
better properties than those of the parental compounds. 
In particular, the hybrid CA(l-13)M(l-13) has in- 
teresting properties. It has melittin size without melittin 
toxicity to red cells. In the plate assay 200 PM gave no 
lysis of normal sheep red cells while with parasite- 
infected human red cells some lysis was observed with 
hybrid 2 at 20 pM, the peptide concentration that gave 
maximum inhibition (fig.2). However, parasite growth 
was already 50% inhibited at IOpM. Hybrid 2, 
CA(l-13)M(l-13), was more active than cecropin A 
agsinst all of the 3 Gram-positive organisms tested 
(table 1). However, the practical use of this compound 
cannot be judged without an extensive toxicity test. 
The ability of melittin to lyse red cells has previously 
been shown to depend on the C-terminal hexapeptide 
[21], and a melittin analog with an intact basic ‘head’ 
and an idealized repeating hydrophobic ‘tail’ structure 
[22] showed a somewhat improved hemolytic activity. 
However, none of the melittin-like hybrid peptides de- 
scribed here were effective hemolytic agents. Our 
prediction was that the melittin-like hybrid 4 should 
lyse red cells but this peptide only produced small turbid 
zones on the SRC plate, and did not give clear evidence 
of lysis. Thus, since neither the two melittin-like 
hybrids 3 and 4, nor the inverted melittin (hybrid 5) 
gave convincing lysis of SRC we conclude that both the 
design of the basic ‘head’ and the location in the C- 
terminus seem to be critical properties for the ability to 
lyse red cells. The inverted melittin (hybrid 5) showed a 
good antibacterial activity against 3 of the 5 test bac- 
teria. Thus, a potent antibacterial activity seesm to be a 
less sequence-dependent property than the lysis of red 
cells. 
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